The midbrain dopaminergic system is a key element in the control of motor activity, cognition, and the motivational effects of drugs of abuse, including nicotine. In this issue of Neuron, Drenan et al. find that a6-containing nicotinic acetylcholine receptors might selectively activate mesolimbic and mesostriatal dopaminergic neurons, enhancing striatal dopamine release and its behavioral consequences.
Nicotine, the primary psychoactive component of tobacco smoke, exerts its actions by acting on endogenous nicotinic acetylcholine receptors (nAChRs), pentameric complexes formed from a portfolio of a and b subunits (a2-a10 and b2-b4) that show unique functional and structural properties depending on the differential association between subunits. nAChRs are ubiquitously expressed throughout the central nervous system at both presynaptic and postsynaptic sites where they cooperate with other neurotransmitter systems to modulate synaptic transmission and plasticity (Dajas-Bailador and Wonnacott, 2004) . Bidirectional crosstalk between the cholinergic and the dopaminergic signaling systems is thought to be crucial for the physiological function of neuronal networks in several neural structures. In particular, in the striatum, the main input station of the basal ganglia neural circuit, interaction between dopaminergic and cholinergic signaling mediates cognitive processes (Calabresi et al., 2006) , motor responses selection, and reward-related information (Cragg, 2006) .
It is generally accepted that the striatum is composed of a dorsal sensorimotor region (dorsal striatum) and a ventral portion that processes limbic information (ventral striatum or nucleus accumbens [NAc] ). Although these regions are very similar with respect to neural cytoarchitecture, their functional roles and dopaminergic projections vary. The dorsal striatum is mainly innervated by associative and sensorimotor areas of the cortex and receives dopaminergic inputs from the substantia nigra pars compacta (SNc) through the so-called ''mesostriatal'' dopaminergic pathway. Conversely, the NAc primarily receives afferents from limbic structures and dopaminergic innervation from the ventral tegmental area (VTA), constituting a primary component of the ''mesolimbic'' pathway. While the dorsal striatum seems to be involved in movement generation and learning, mesolimbic dopaminergic neurons of the VTA play a crucial role in mediating the reinforcing effects of natural rewards and the motivational effects of a wide variety of addictive drugs, including nicotine (Laviolette and van der Kooy, 2004) . Both the VTA and the SNc contain dopaminergic and GABAergic neurons Laviolette and van der Kooy, 2004) and express nAChRs, although their subunit composition profiles seem to substantially differ (Keath et al., 2007) .
Nicotine can activate midbrain dopaminergic neurons and presynaptic dopaminergic terminals in the striatum (Calabresi et al., 1989; Picciotto et al., 1998; Pidoplichko et al., 1997; Zhou et al., 2001 ), leading to dopamine (DA) release and thus exerting a major role in modulating the dopaminergic control of both motor activity and reward. The original description of the direct nicotinic action on VTA neurons suggested that endogenous acetylcholine (ACh) is able to activate postsynaptic receptors located on midbrain dopaminergic neurons (Calabresi et al., 1989) . However, VTA and SNc dopaminergic neurons seem to be differentially modulated by nicotine, leading to more profound effects in VTA than SNc (Keath et al., 2007) , supporting the observation that in vivo nicotine administration elicits stronger DA release in the NAc than in the dorsal striatum (Di Chiara and Imperato, 1988) .
In the VTA, GABAergic neurons express a4b2 nAChRs, while glutamatergic terminals express a7-containing nAChRs that show less desensitization (Keath et al., 2007) . Accordingly, it has been hypothesized that exposure to nicotine might initially result in increased firing of VTA GABAergic neurons through the activation of a7-containing nAChRs, followed by their desensitization, leading to the disinhibition and firing of DA neurons. This latter event might be also enabled by the more prolonged activation of a7-containing nAChRs expressed on glutamatergic terminals (Keath et al., 2007) . Although significant advances have been made in understanding nAChR-mediated control of dopaminergic transmission, a number of questions still remain unanswered and the complex issue of interpreting the role of the large portfolio of different nAChR subtypes expressed by VTA and SNc neurons is far from being solved. In this issue of Neuron, Drenan and colleagues provide new insights into the complex mechanisms underlying the ACh-mediated control of dopaminergic signaling (Drenan et al., 2008) . In particular, the authors generated mice with gain-of-function a6-containing nAChRs in order to selectively amplify and characterize the cholinergic control of DA release mediated by these receptors. Although mutant mice exhibited normal levels and localization of neuronal nAChRs, the results obtained by the authors with behavioral, electrophysiological, and molecular biology techniques suggest that a6-containing nAChRs might play a specific and crucial role in regulating DA release and its behavioral consequences.
Mutant mice were markedly hyperactive in comparison to WT mice and did not show habituation when placed in a novel environment. Nicotine administration resulted in a strong activation of locomotion in mutant mice without having any effect in WT animals, and interestingly, this effect on locomotor behavior was not changed after repeated nicotine injections.
After separating tissue samples of the mesostriatal and mesolimbic pathways, the authors measured nicotine-stimulated DA release from striatal synaptosomes of mutant and WT mice and showed that the selective activation of a6-containing nAChRs is capable of stimulating DA release. Interestingly, the authors uncovered no difference in GABA release, suggesting that striatal GABA release could be independent from the stimulation of a6-containing nAChRs.
With electrophysiological recordings from VTA/SNc dopaminergic neurons, the authors then demonstrated that neurons from mutant mice are markedly hypersensitive to nicotine, showing larger inward currents after nicotine puffs. Interestingly, the authors noticed greater fluctuations in the holding current in mutant VTA/SNc neurons, which was absent after a6 blockade, suggesting its dependence on the tonic activation of some a6-containing channels. The authors then more selectively investigated the electrophysiology of midbrain dopaminergic versus GABAergic neurons, leading to one of their central discoveries. Indeed, the hypersensitive nicotinic responses were found to be present in dopaminergic neurons, but not GABAergic neurons, suggesting that functional a6-containing nAChRs, in contrast to a4-containing nAChRs, might be restricted to dopaminergic neurons in the midbrain.
It is difficult to understand whether the observed effects of low-dose nicotine on locomotor behavior are preferentially based on a ''motivational'' effect caused by the stimulation of the mesolimbic pathway or on a more selective ''motor'' effect consequent to the activation of the mesostriatal pathway. This issue, unfortunately, has not been directly addressed with behavioral experiments. Nevertheless, the direct comparison of the results of DA release with the electrophysiological experiments seems to suggest that the mesolimbic pathway is more influenced by a6-containing nAChR stimulation than the mesostriatal pathway is.
The experimental and clinical implications of this research are considerable, and they might suggest future research directions. Indeed, pathological conditions ranging from Parkinson's disease to drug addiction might benefit from a drug able to modulate the dopaminergic system in an indirect manner. In particular, the possibility of selectively influencing, either positively or negatively, dopaminergic transmission via the manipulation of a6-containing nAChRs opens the way to the development of new pharmacological compounds for the treatment of neuropsychiatric diseases characterized by an altered dopaminergic signaling. The potential usefulness of a6-containing nAChR manipulation as an effective therapeutic strategy seems to be also supported by the interesting observation that, at least in the presented experimental model, the repeated activation of these receptors produced neither tolerance nor sensitization, suggesting potentially reduced risks of drug abuse.
Although the interesting results obtained by Drenan and colleagues shed light on the mechanisms underlying the ACh-mediated control of dopaminergic transmission, the provided data also raise several crucial and yet unanswered questions.
Compelling evidence suggests that the interaction between the cholinergic and the dopaminergic systems is not unidirectional, but mutual. Indeed, in different neuronal structures, but particularly in the striatum, a bidirectional crosstalk occurs between these two neurotransmitters to physiologically modulate synaptic transmission and, notably, synaptic plasticity (Calabresi et al., 2006) . Moreover, this DA/ACh interaction is not only based on the activation of nAChRs, but also on the stimulation of muscarinic ACh receptors (Calabresi et al., 2006) . These latter observations provide several interesting points of discussion. What is the net effect of the complex mechanisms by which the dopaminergic and the cholinergic systems influence each other in the striatum? For example, striatal cholinergic interneurons express both D1-like and D2-like DA receptors and can be either excited or inhibited by DA (Calabresi et al., 2006) , further complicating the issue of the intrastriatal DA/ACh interactions. What is the relative role played by muscarinic ACh receptors in the ACh-mediated depolarization of SNc and VTA neurons in physiological conditions? ACh has indeed been demonstrated to depolarize SNc and VTA neurons through muscarinic M1-like receptors (Lacey et al., 1990) , suggesting that in the absence of nAChR stimulation by exogenous nicotine, the effects of ACh might also be crucially dependent on its effects on muscarinic receptors (Figure 1) .
A third question regards the potential downstream effects exerted by a6-containing nAChRs in the regulation of neuroplasticity. Indeed, a very important role seems to be played by long-term synaptic plasticity both in the striatum and in dopaminergic midbrain during both physiological learning and pathological conditions such as Parkinson's disease or drug addiction. A considerable amount of research is aimed at investigating the substrate of synaptic plasticity alterations occurring during these pathological conditions.
In this context, the work presented here might provide a new basis for the development of pharmacological compounds able to restore synaptic plasticity in these pathological scenarios.
The authors' finding that a6-containing nAChRs play a selective role in the modulation of DA release in both the NAc and in the dorsal striatum might open new neuropharmacological horizons, allowing an indirect but extremely selective control of the dopaminergic signaling system. Further experimental investigations are necessary to prove the validity of these hypotheses. Simplified representative scheme of the complex interactions occurring between the dopaminergic and the cholinergic signaling systems regulating reward and motor activity. The selective presence of a6-containing nicotinic ACh receptors on dopaminergic neurons influences DA release both in the ventral and in the dorsal striatum. ACh also exerts a modulatory role in the basal ganglia via M1-like (M1) and M2-like (M2) muscarinic ACh receptors. At the same time, striatal DA regulates ACh release via D1-like (D1) and D2-like (D2) DA receptors. Abbreviation: PPN, pedunculopontine nucleus.
